AI-generated · cited to primary sources · not investment advice · How we research
Indegene
Our verdict on Indegene isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
The delivery headcount with healthcare expertise reached 24.8%, slightly exceeding the upper bound of the previously guided range. (3 exceeded, 2 met across 5 tracked commitments)
“But we certainly are looking forward to a growth rate, which is higher than what we saw in the past year and even the start of this year.”
Revenue per employee crossed the $70K annual mark, which management claims is the highest in the industry, driven by AI-led productivity scaling. (1 exceeded, 1 met across 2 tracked commitments)
“But consistently over the past 4, 5 years that has been in the vicinity of 2% of our revenue would be in that 1.7%, 1.8% going towards 2%, but would not be materially different from our plan going forward.”
Management confirmed the continued existence of a dedicated 10-person M&A team and announced two recent acquisitions (BioPharm and WARN & Co). (1 met across 1 tracked commitment)
“The acquisition of Cake Kommunikations is subject to meeting the closing conditions as defined in the SPA which are yet to be completed as on 31 December 2025; expected closure in Q4 FY26”
The company successfully increased the number of clients in the $10-25 million bracket from 7 to 9 QoQ, while maintaining 2 clients in the >$25 million bracket. Total $1Mn+ clients remained stable at 40. (1 met, 1 exceeded, 1 in progress across 3 tracked commitments)
“But we feel good about if, let's say, call it, a few quarters down the line, our client pyramid is going to start looking stronger. 10 to 25 moving to 25-plus, fingers crossed. We're also hoping to break the 50 mark, right, having a customer move over there.”
The Tectonic offering is showing early traction, doubling its customer count from 2 in Q1 to 4 in Q2 and clocking $2 million in revenue for H1 FY26. (1 in progress, 1 met across 2 tracked commitments)
“Among the significant wins during the quarter, there were 2 large deals of 3 million-plus ACV... Both these are start expected to start in Q3 and ramp up over the next 3, 4 quarters. Additionally, we had 4 deal wins in the 1 million to 3 million ACV range.”
See the full cited Management analysis of Indegene
How durable is the business?
The segment remains the primary revenue engine, growing 5.1% sequentially in Q4 FY25, though its total revenue share has slightly moderated from 71% to approximately 56% as other segments grew faster. (5 expanding)
“Core segments (ECS & EMS) grew 5.1% sequentially... ECS [Q4 FY25] 4,225”
While the company lost volume in two major accounts, they successfully grew their 'USD 1 million plus' client base and won a significant USD 5 million plus ACV deal with a Top 10 EU pharma company, indicating continued stickiness in large-scale enterprise deals. (5 expanding)
“56% (63%) Revenue from Top 20 Global Biopharma* Companies; 52 (40) Clients with $1 Million+ Revenue”
The company strengthened its technological moat with the launch of 'Cortex', a flagship GenAI platform specifically built for the life sciences industry. (5 expanding across 1 engine)
“Enterprise Medical Solutions | Dec 31, 2025 | 25.3 | YoY 16.3%”
The segment is seeing strong growth and an uptick in revenues following the integration of the Trilogy acquisition, which added high-end medical writing capabilities. Growth is coming from both Top 20 and mid-tier pharma companies. (3 expanding)
“The core enterprise businesses, both commercial and medical together growing at a healthy rate of 5.1%... Trilogy acquisition... has given a bit of an uptick in revenues.”
EMS is the fastest-growing core segment, expanding by 33.6% year-on-year, driven by high demand for regulatory and pharmacovigilance services. (4 expanding, 1 contracting)
“North America | Dec 31, 2025 | 71.8 | YoY 35.7%”
See the full cited Business Model analysis of Indegene
Where does growth come from?
Active client relationships have grown YoY from 65 to 70, though there was a slight dip from the peak of 73 in the previous quarter. (2 steady, 1 accelerating across 3 signals)
“Total employees 5,497 (4,880 in Dec 31, 2024)”
The company is expanding its global footprint, with North American revenue growing significantly, now representing nearly 72% of total sales. — North America Revenue Contribution: 35.7% YoY (+1 more signal)
“North America... Dec 31, 2025: 71.8... YoY Growth 35.7%”
The company is successfully moving clients into higher spending tiers, with the count of $25Mn+ clients increasing from 2 to 3 this quarter. (2 accelerating, 1 reversing, 2 decelerating across 5 signals)
“86 (76) Active Client Relationships”
Profitability is expected to improve as the company integrates its recent acquisitions and reduces one-time costs associated with these deals. — Adjusted EBITDA: 15.7% YoY (+1 more signal)
“As integration synergies are realized, acquisition-related costs taper off, and growth momentum continues, we expect profitability to continue to strengthen”
Active client acquisition is accelerating on an annual basis (up from 63 to 73), although there was a slight sequential dip from the previous quarter. (4 accelerating, 1 reversing across 5 signals)
“Higher Depreciation and Amortization as non-cash charges, increased from INR234 million in Quarter 2 to INR396 million in Quarter 3, reflecting amortization of the intangibles from the recent acquisition.”
See the full cited Future Growth analysis of Indegene
What could break the thesis?
The risk is intensifying as North American revenue share increased from 69.3% in Q3 to 71.9% in Q4, further concentrating geographic risk. (1 intensifying, 4 stable, 2 high-severity)
“Revenue by customer geography (in %)... North America 71.8%”
The risk is intensifying in terms of immediate financial impact as M&A expenses surged 507% QoQ (from 7 Mn to 42 Mn). However, management has integrated two new entities (BioPharm and WARN & Co.) to align with future growth. (2 intensifying, 2 emerging, 1 easing, 1 high-severity)
“Higher Depreciation and Amortization as non-cash charges, increased from INR234 million in Quarter 2 to INR396 million in Quarter 3, reflecting amortization of the intangibles from the recent acquisition... Both these impacted about 205 basis points at a PBT level and 156 basis points at the PAT level.”
This risk is stable/intensifying as management confirmed they have already started incurring costs for large deals in the pipeline that have not yet gone live. (3 stable, 1 intensifying)
“Quarter 3 also witnessed elevated costs related to upfront investments and go-live costs in large deals won in the recent past”
The risk remains high but stable; Top 20 accounts contributed 76.2% of revenues this quarter, showing a slight increase in concentration but management notes these accounts are 'business as usual' and stabilizing after previous churn. (2 stable, 1 intensifying, 2 easing)
“there are pockets where we have proactively gone ahead and offered certain benefits to our customers coming largely out of sharing the Gen AI-led productivity benefits that we anticipate.”
Concentration in Biopharma has intensified, now accounting for 94% of revenue in Q4 FY25 compared to 93.8% for the full year, increasing vulnerability to sector-specific pressures like the 'Patent Cliff' or IRA pricing. (1 intensifying, 4 easing, 2 high-severity)
“Revenue from Top 20 customers... 74%... Q3 FY26 TTM”
See the full cited Risk analysis of Indegene
Read the full thesis on Indegene
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.